[{"id":"714db3ca-404e-4222-9a0f-e2cca6ea14dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT07483567","created_at":"2026-03-28T01:36:25.975Z","updated_at":"2026-03-28T01:36:25.975Z","phase":"Phase 2","brief_title":"IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT07483567","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • arcotatug tavatecan (TAK-921)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 03/30/2026","start_date":" 03/30/2026","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 06/30/2031","study_completion_date":" 06/30/2031","last_update_posted":"2026-03-19"},{"id":"488850a4-401a-418b-88e8-32f7b6c5f0dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06038578","created_at":"2023-09-15T18:09:55.230Z","updated_at":"2025-02-25T13:41:43.311Z","phase":"Phase 2","brief_title":"A Study of TRK-950 When Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer","source_id_and_acronym":"NCT06038578","lead_sponsor":"Toray Industries, Inc","biomarkers":" CAPRIN1","pipe":"","alterations":" ","tags":["CAPRIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Cyramza (ramucirumab) • TRK-950"],"overall_status":"Recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 10/04/2023","start_date":" 10/04/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-21"},{"id":"6d7c8fa9-67d2-4bc9-bef1-9bdadb373194","acronym":"","url":"https://clinicaltrials.gov/study/NCT04863430","created_at":"2021-04-28T12:52:46.950Z","updated_at":"2025-02-25T13:49:08.094Z","phase":"Phase 2","brief_title":"Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach","source_id_and_acronym":"NCT04863430","lead_sponsor":"Peking University","biomarkers":" HER-2 • GPC3 • SALL4","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["HER-2 • GPC3 • SALL4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/11/2021","start_date":" 05/11/2021","primary_txt":" Primary completion: 07/06/2023","primary_completion_date":" 07/06/2023","study_txt":" Completion: 07/06/2023","study_completion_date":" 07/06/2023","last_update_posted":"2025-02-21"},{"id":"b94d3fe3-9040-4df9-8c37-231f34f9f98f","acronym":"POLESTAR","url":"https://clinicaltrials.gov/study/NCT05268510","created_at":"2022-03-07T18:53:55.391Z","updated_at":"2025-02-25T13:54:16.446Z","phase":"Phase 2","brief_title":"Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma","source_id_and_acronym":"NCT05268510 - POLESTAR","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" HER-2 • PD-L1 • CD8 • CD4","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1 • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • capecitabine • oxaliplatin"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 09/15/2022","start_date":" 09/15/2022","primary_txt":" Primary completion: 08/27/2024","primary_completion_date":" 08/27/2024","study_txt":" Completion: 01/09/2025","study_completion_date":" 01/09/2025","last_update_posted":"2025-02-20"},{"id":"3875d166-2701-445e-aa30-32ca8986f0a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03092518","created_at":"2021-01-18T15:14:06.092Z","updated_at":"2025-02-25T14:01:14.625Z","phase":"Phase 2","brief_title":"Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology","source_id_and_acronym":"NCT03092518","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • mitomycin • Jelmyto (mitomycin urothelial gel)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 06/05/2017","start_date":" 06/05/2017","primary_txt":" Primary completion: 04/05/2024","primary_completion_date":" 04/05/2024","study_txt":" Completion: 07/24/2024","study_completion_date":" 07/24/2024","last_update_posted":"2025-02-19"},{"id":"4bf8a0e4-ad61-4bd3-8b19-15b271d96a0b","acronym":"D9750C00001","url":"https://clinicaltrials.gov/study/NCT06005493","created_at":"2023-08-22T15:08:52.377Z","updated_at":"2025-02-25T14:10:00.557Z","phase":"Phase 1/2","brief_title":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT06005493 - D9750C00001","lead_sponsor":"AstraZeneca","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive • CLDN1 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive • CLDN1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD5863"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 07/11/2023","start_date":" 07/11/2023","primary_txt":" Primary completion: 12/16/2026","primary_completion_date":" 12/16/2026","study_txt":" Completion: 12/16/2026","study_completion_date":" 12/16/2026","last_update_posted":"2025-02-18"},{"id":"40d264c0-ef98-4585-8486-d32526145561","acronym":"","url":"https://clinicaltrials.gov/study/NCT06123338","created_at":"2023-11-08T22:13:20.652Z","updated_at":"2025-02-25T14:42:29.112Z","phase":"Phase 2","brief_title":"A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer","source_id_and_acronym":"NCT06123338","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • capecitabine • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 11/30/2027","primary_completion_date":" 11/30/2027","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2025-02-14"},{"id":"6c9db75b-36fc-4c6c-ad67-8b4c2281f714","acronym":"MRD-GI","url":"https://clinicaltrials.gov/study/NCT05482516","created_at":"2022-08-01T14:54:43.578Z","updated_at":"2025-02-25T15:12:57.370Z","phase":"Phase 3","brief_title":"Evaluating Novel Therapies in ctDNA Positive GI Cancers","source_id_and_acronym":"NCT05482516 - MRD-GI","lead_sponsor":"Georgetown University","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/29/2023","start_date":" 03/29/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-02-13"},{"id":"bcfa1353-7be6-4150-b82c-bf13212f8a0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05836584","created_at":"2023-05-01T14:03:52.795Z","updated_at":"2025-02-25T15:13:28.038Z","phase":"Phase 2","brief_title":"Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer","source_id_and_acronym":"NCT05836584","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • docetaxel • capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 12/06/2023","start_date":" 12/06/2023","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2025-02-13"},{"id":"a1ad25fe-9fca-497e-84b3-6dc3bccd8870","acronym":"CHM-2101-001","url":"https://clinicaltrials.gov/study/NCT06055439","created_at":"2023-09-26T16:12:30.309Z","updated_at":"2025-02-25T15:45:14.681Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy","source_id_and_acronym":"NCT06055439 - CHM-2101-001","lead_sponsor":"Chimeric Therapeutics","biomarkers":" CDH17","pipe":" | ","alterations":" CDH1 expression","tags":["CDH17"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 05/15/2024","start_date":" 05/15/2024","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-02-11"},{"id":"95c0229a-8b91-4b07-bbd8-e69278f6a209","acronym":"DESTINY-Gastric03","url":"https://clinicaltrials.gov/study/NCT04379596","created_at":"2021-01-18T21:09:02.628Z","updated_at":"2025-02-25T16:32:08.037Z","phase":"Phase 2","brief_title":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","source_id_and_acronym":"NCT04379596 - DESTINY-Gastric03","lead_sponsor":"AstraZeneca","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • cisplatin • Imfinzi (durvalumab) • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • rilvegostomig (AZD2936) • volrustomig (MEDI5752)"],"overall_status":"Recruiting","enrollment":" Enrollment 413","initiation":"Initiation: 06/03/2020","start_date":" 06/03/2020","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2026","study_completion_date":" 07/30/2026","last_update_posted":"2025-02-07"},{"id":"f231b1ba-c963-4fcd-a957-1503f6a6f741","acronym":"SGNTUC 024","url":"https://clinicaltrials.gov/study/NCT04430738","created_at":"2021-01-18T21:20:17.873Z","updated_at":"2025-02-25T16:37:54.749Z","phase":"Phase 1/2","brief_title":"Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers","source_id_and_acronym":"NCT04430738 - SGNTUC 024","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • 5-fluorouracil • capecitabine • oxaliplatin • Tukysa (tucatinib) • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 09/15/2020","start_date":" 09/15/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-02-06"},{"id":"b2f66c0e-6c9b-4463-9368-140116887239","acronym":"ACROPOLI","url":"https://clinicaltrials.gov/study/NCT04802876","created_at":"2021-03-17T15:57:42.481Z","updated_at":"2025-02-25T15:44:25.480Z","phase":"Phase 2","brief_title":"Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors","source_id_and_acronym":"NCT04802876 - ACROPOLI","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" PD-1","pipe":" | ","alterations":" PD-1 expression","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 04/12/2021","start_date":" 04/12/2021","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-04"},{"id":"c2e2b93b-ca84-4ba4-bfe8-8c9d233408b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03030404","created_at":"2021-01-18T14:54:58.353Z","updated_at":"2025-02-25T16:51:48.335Z","phase":"","brief_title":"Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer","source_id_and_acronym":"NCT03030404","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CTNNA1","pipe":"","alterations":" ","tags":["CTNNA1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 684","initiation":"Initiation: 01/27/2017","start_date":" 01/27/2017","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2025-02-04"},{"id":"8a36dc46-7e94-43f5-8360-2cd36c81ca39","acronym":"","url":"https://clinicaltrials.gov/study/NCT04034251","created_at":"2021-01-18T19:47:54.419Z","updated_at":"2025-02-25T17:00:07.598Z","phase":"Phase 2","brief_title":"Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis","source_id_and_acronym":"NCT04034251","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • capecitabine"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 06/09/2020","start_date":" 06/09/2020","primary_txt":" Primary completion: 02/25/2023","primary_completion_date":" 02/25/2023","study_txt":" Completion: 09/05/2024","study_completion_date":" 09/05/2024","last_update_posted":"2025-02-03"},{"id":"6ae1af87-4593-48e3-aff5-d1191e4709dc","acronym":"TORCH-G","url":"https://clinicaltrials.gov/study/NCT06728657","created_at":"2025-02-26T07:20:14.599Z","updated_at":"2025-02-26T07:20:14.599Z","phase":"Phase 2","brief_title":"Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma","source_id_and_acronym":"NCT06728657 - TORCH-G","lead_sponsor":"Fudan University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tyvyt (sintilimab) • capecitabine • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-12-11"},{"id":"a35ae63d-7bfa-40bf-b911-fec1b0dea308","acronym":"DECIPHER","url":"https://clinicaltrials.gov/study/NCT05965479","created_at":"2023-07-31T17:08:57.339Z","updated_at":"2025-02-25T15:01:01.413Z","phase":"Phase 2","brief_title":"Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer","source_id_and_acronym":"NCT05965479 - DECIPHER","lead_sponsor":"University of Southampton","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 04/10/2024","start_date":" 04/10/2024","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 04/30/2028","study_completion_date":" 04/30/2028","last_update_posted":"2024-11-11"},{"id":"b90611f6-d5aa-4754-9793-ea6b3cb720a3","acronym":"EA2183","url":"https://clinicaltrials.gov/study/NCT04248452","created_at":"2021-01-18T20:38:53.831Z","updated_at":"2025-02-25T16:32:04.439Z","phase":"Phase 3","brief_title":"Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body","source_id_and_acronym":"NCT04248452 - EA2183","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" HER-2 • CD4","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 05/26/2020","start_date":" 05/26/2020","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2024-11-05"},{"id":"e7994b16-b13b-48b5-b181-6c32d8854d0e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06646783","created_at":"2025-02-26T10:15:50.233Z","updated_at":"2025-02-26T10:15:50.233Z","phase":"Phase 1","brief_title":"Phase IIT Trial of SNA014","source_id_and_acronym":"NCT06646783","lead_sponsor":"SmartNuclide Biopharma","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 10/20/2024","start_date":" 10/20/2024","primary_txt":" Primary completion: 10/20/2025","primary_completion_date":" 10/20/2025","study_txt":" Completion: 11/20/2025","study_completion_date":" 11/20/2025","last_update_posted":"2024-10-17"},{"id":"fce3d556-d1c0-4ebd-973c-c01efbeeac27","acronym":"PLATFORM","url":"https://clinicaltrials.gov/study/NCT02678182","created_at":"2021-01-17T17:56:06.364Z","updated_at":"2025-02-25T14:57:30.468Z","phase":"Phase 2","brief_title":"Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial","source_id_and_acronym":"NCT02678182 - PLATFORM","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Imfinzi (durvalumab) • capecitabine • Rubraca (rucaparib) • Cyramza (ramucirumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 494","initiation":"Initiation: 02/01/2015","start_date":" 02/01/2015","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-09-19"},{"id":"6df41b1d-a29a-4ea2-834c-37c31e7d70aa","acronym":"HERA","url":"https://clinicaltrials.gov/study/NCT06550063","created_at":"2025-02-27T08:05:38.522Z","updated_at":"2025-02-27T08:05:38.522Z","phase":"","brief_title":"HER2 Status in Esophagogastric Adenocarcinoma and Its Associations With Patient's Clinicopathological Outcomes","source_id_and_acronym":"NCT06550063 - HERA","lead_sponsor":"St. James's Hospital, Ireland","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"],"overall_status":"Recruiting","enrollment":" Enrollment 2188","initiation":"Initiation: 08/20/2024","start_date":" 08/20/2024","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2024-08-13"},{"id":"784231b9-195e-4cdb-8b0c-3f60c54cd03b","acronym":"KEYNOTE-098","url":"https://clinicaltrials.gov/study/NCT02443324","created_at":"2021-01-17T17:34:42.987Z","updated_at":"2025-02-25T16:14:44.151Z","phase":"Phase 1","brief_title":"A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer","source_id_and_acronym":"NCT02443324 - KEYNOTE-098","lead_sponsor":"Eli Lilly and Company","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Cyramza (ramucirumab)"],"overall_status":"Completed","enrollment":" Enrollment 175","initiation":"Initiation: 07/29/2015","start_date":" 07/29/2015","primary_txt":" Primary completion: 08/31/2018","primary_completion_date":" 08/31/2018","study_txt":" Completion: 04/12/2022","study_completion_date":" 04/12/2022","last_update_posted":"2024-07-31"},{"id":"939b964b-5b2e-40f9-937f-f11540ceea21","acronym":"PRODIGE 59 - DURIGAST","url":"https://clinicaltrials.gov/study/NCT03959293","created_at":"2021-01-18T19:29:04.858Z","updated_at":"2025-02-25T15:08:33.662Z","phase":"Phase 2","brief_title":"Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT03959293 - PRODIGE 59 - DURIGAST","lead_sponsor":"Federation Francophone de Cancerologie Digestive","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imfinzi (durvalumab) • 5-fluorouracil • Imjudo (tremelimumab-actl) • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 07/17/2019","start_date":" 07/17/2019","primary_txt":" Primary completion: 03/15/2022","primary_completion_date":" 03/15/2022","study_txt":" Completion: 11/27/2024","study_completion_date":" 11/27/2024","last_update_posted":"2024-07-08"},{"id":"807435ea-861d-4d9d-b38f-cc3478e08f0f","acronym":"SEQUEL","url":"https://clinicaltrials.gov/study/NCT04069273","created_at":"2021-01-18T19:56:49.913Z","updated_at":"2025-02-25T16:09:26.660Z","phase":"Phase 2","brief_title":"Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma","source_id_and_acronym":"NCT04069273 - SEQUEL","lead_sponsor":"Harry H Yoon","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • paclitaxel • Cyramza (ramucirumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 06/11/2025","primary_completion_date":" 06/11/2025","study_txt":" Completion: 12/10/2025","study_completion_date":" 12/10/2025","last_update_posted":"2024-07-02"}]